biguanides has been researched along with Glioblastoma in 2 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roh, TH | 1 |
| Lee, JH | 1 |
| Kim, SJ | 1 |
| Shim, JK | 1 |
| Park, J | 1 |
| Yoon, SJ | 1 |
| Teo, WY | 1 |
| Kim, SH | 1 |
| Chang, JH | 1 |
| Kang, SG | 1 |
| Barbieri, F | 1 |
| Bosio, AG | 1 |
| Pattarozzi, A | 1 |
| Tonelli, M | 1 |
| Bajetto, A | 1 |
| Verduci, I | 1 |
| Cianci, F | 1 |
| Cannavale, G | 1 |
| Palloni, LMG | 1 |
| Francesconi, V | 1 |
| Thellung, S | 1 |
| Fiaschi, P | 1 |
| Mazzetti, S | 1 |
| Schenone, S | 1 |
| Balboni, B | 1 |
| Girotto, S | 1 |
| Malatesta, P | 1 |
| Daga, A | 1 |
| Zona, G | 1 |
| Mazzanti, M | 1 |
| Florio, T | 1 |
2 other studies available for biguanides and Glioblastoma
| Article | Year |
|---|---|
A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.
Topics: Adenosine Triphosphate; Animals; Biguanides; Brain Neoplasms; Cell Line, Tumor; Energy Metabolism; G | 2022 |
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives.
Topics: Biguanides; Cell Line, Tumor; Chloride Channels; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2022 |